Skip to main content

IMPACTO DELA FUNCION Y LA ANTIGENICIDAD DE LA GLUCOPROTEINA DE LA ENVUELTA DE VIH-1 EN EL CONTROL DE ELITE DE LA REPLICACION VIRAL

PI20/00093

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Execution centre INSTITUTO DE INVESTIGACION GERMANS TRIAS I PUJOL (IGTP)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals

  • Trinité, Benjamin|||0000-0003-3809-042X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Urrea, Víctor|||0000-0002-2577-856X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Rodon, Jordi|||0000-0002-1032-9091
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Guallar, Victor|||0000-0002-4580-1114
  • Lepore, Rosalba
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Trujillo, Glòria
  • Trapé, Jaume
  • González-Fernández, Carolina
  • Flor, Antonia
  • Pérez-Vidal, Rafel
  • Toledo, Ruth
  • Chamorro, Anna
  • Paredes, Roger|||0000-0002-6553-691X
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Grau, Eulàlia|||0000-0002-2442-9165
  • Massanella, Marta|||0000-0002-3326-151X
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
With the spread of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a need to assess the protection conferred by both previous infections and current vaccination. Here we tested the neutralizing activity of infected and/or vaccinated individuals against pseudoviruses expressing the spike of the original SARS-CoV-2 isolate Wuhan-Hu-1 (WH1), the D614G mutant and the B.1.1.7 variant. Our data show that parameters of natural infection (time from infection and nature of the infecting variant) determined cross-neutralization. Uninfected vaccinees showed a small reduction in neutralization against the B.1.1.7 variant compared to both the WH1 strain and the D614G mutant. Interestingly, upon vaccination, previously infected individuals developed more robust neutralizing responses against B.1.1.7, suggesting that vaccines can boost the neutralization breadth conferred by natural infection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

  • Pradenas, Edwards|||0000-0001-5162-8920
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Urrea, Víctor|||0000-0002-2577-856X
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Rodon, Jordi|||0000-0002-1032-9091
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Guallar, Victor|||0000-0002-4580-1114
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Paredes, Roger|||0000-0002-6553-691X
  • Mateu, Lourdes|||0000-0001-7223-7611
  • Chamorro, Anna
  • Toledo, Ruth
  • Massanella, Marta|||0000-0002-3326-151X
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Blanco, Julià|||0000-0002-2225-0217
To understand the determinants of long-term immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the concurrent impact of vaccination and emerging variants, we follow a prospective cohort of 332 patients with coronavirus disease 2019 (COVID-19) over more than a year after symptom onset. We evaluate plasma-neutralizing activity using HIV-based pseudoviruses expressing the spike of different SARS-CoV-2 variants and analyze them longitudinally using mixed-effects models. Long-term neutralizing activity is stable beyond 1 year after infection in mild/asymptomatic and hospitalized participants. However, longitudinal models suggest that hospitalized individuals generate both short- and long-lived memory B cells, while the responses of non-hospitalized individuals are dominated by long-lived B cells. In both groups, vaccination boosts responses to natural infection. Long-term (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice

  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Romero-Durana, Miguel|||0000-0001-6779-8553
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Avila-Nieto, Carlos
  • Pérez, Mónica
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Andrés, Cristina|||0000-0002-3200-0895
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Pumarola Suñé, Tomàs|||0000-0002-5171-7461
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Guallar, Victor|||0000-0002-4580-1114
  • Lepore, Rosalba
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Urrea, Víctor|||0000-0002-2577-856X
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Blanco, Julià|||0000-0002-2225-0217
The emerging SARS-CoV-2 variants of concern (VOCs) may display enhanced transmissibility, more severity and/or immune evasion; however, the pathogenesis of these new VOCs in experimental SARS-CoV-2 models or the potential infection of other animal species is not completely understood. Here we infected K18-hACE2 transgenic mice with B.1, B.1.351/Beta, B.1.617.2/Delta and BA.1.1/Omicron isolates and demonstrated heterogeneous infectivity and pathogenesis. B.1.351/Beta variant was the most pathogenic, while BA.1.1/Omicron led to lower viral RNA in the absence of major visible clinical signs. In parallel, we infected wildtype (WT) mice and confirmed that, contrary to B.1 and B.1.617.2/Delta, B.1.351/Beta and BA.1.1/Omicron can infect them. Infection in WT mice coursed without major clinical signs and viral RNA was transient and undetectable in the lungs by day 7 post-infection. In silico modeling supported these findings by predicting B.1.351/Beta receptor binding domain (RBD) mutations result in an increased affinity for both human and murine ACE2 receptors, while BA.1/Omicron RBD mutations only show increased affinity for murine ACE2.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses

  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Urrea, Víctor|||0000-0002-2577-856X
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Blanco, Pau
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Molinos-Albert, Luis Manuel|||0000-0001-5447-6803
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Avila-Nieto, Carlos
  • Varela, Ismael|||0000-0002-3825-372X
  • Cervera Gracia, Laura|||0000-0002-3639-2793
  • Gutiérrez-Granados, Sònia
  • Segura, Maria Mercedes
  • Gòdia, Francesc|||0000-0002-4060-9887
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
Antigen display on the surface of Virus-Like Particles (VLPs) improves immunogenicity compared to soluble proteins. We hypothesised that immune responses can be further improved by increasing the antigen density on the surface of VLPs. In this work, we report an HIV-1 Gag-based VLP platform engineered to maximise the presence of antigen on the VLP surface. An HIV-1 gp41-derived protein (Min), including the C-terminal part of gp41 and the transmembrane domain, was fused to HIV-1 Gag. This resulted in high-density MinGag-VLPs. These VLPs demonstrated to be highly immunogenic in animal models using either a homologous (VLP) or heterologous (DNA/VLP) vaccination regimen, with the latter yielding 10-fold higher anti-Gag and anti-Min antibody titres. Despite these strong humoral responses, immunisation with MinGag-VLPs did not induce neutralising antibodies. Nevertheless, antibodies were predominantly of an IgG2b/IgG2c profile and could efficiently bind CD16-2. Furthermore, we demonstrated that MinGag-VLP vaccination could mediate a functional effect and halt the progression of a Min-expressing tumour cell line in an in vivo mouse model.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention

  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
The development of HIV prophylactic vaccines is facing an impasse, since all phase IIb/III clinical trials were halted in 2023 without demonstrating efficacy. Thus, the field is in need of developing novel immunogens and vaccination strategies that induce broadly neutralising antibodies together with potent Fc-dependent effector functions, as well as protective cross-reactive CD4 and CD8 T cell responses. Nucleic acid vaccines, particularly mRNA vaccines, have been one of the major groundbreaking advances in the current decade. Nucleic acid vaccines may help recalibrate the HIV vaccine field towards the use of delivery systems that allow the proper expression of immunogens as a sole antigen (i.e., membrane-bound trimeric envelope glycoproteins) or even to be displayed in a multiantigen platform that will be synthesised by the host. In this review, we will summarise how the multiple HIV vaccine strategies pursued in the last 40 years of HIV research have driven current vaccine development, which are the most relevant immunogens identified so far to induce balanced adaptive immune responses, and how they can benefit from the acceptance of nucleic acid vaccines in the market by reducing the limitations of previous delivery systems. The incorporation of nucleic acid vaccines into the current heterogeneous repertoire of vaccine platforms may represent an invaluable opportunity to reignite the fight against HIV.